Arena Completes Enrollment of PAH Patients in Ralinepag Phase 2 Study
Arena Pharmaceuticals has completed enrolling patients with pulmonary arterial hypertension (PAH) in its Phase 2 clinical trial evaluating the effectiveness of ralinepag (APD811), the company’s investigational drug for the treatment of PAH. “This marks an important step in the development of ralinepag and is evidence of our strategic focus on…